Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

GSK690693

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

GSK

Drug class:

AKT inhibitor

Related drugs:

‹

›

AKT3 expression	Triple Negative Breast Cancer	AKT3 expression	Triple Negative Breast Cancer	GSK690693 Resistant: D – Preclinical GSK690693 Resistant : D	GSK690693 Resistant: D – Preclinical GSK690693 Resistant : D
BBOX1 underexpression	Renal Cell Carcinoma	BBOX1 underexpression	Renal Cell Carcinoma	GSK690693 Sensitive: D – Preclinical GSK690693 Sensitive : D	GSK690693 Sensitive: D – Preclinical GSK690693 Sensitive : D
ZNF765 overexpression	Hepatocellular Cancer	ZNF765 overexpression	Hepatocellular Cancer	GSK690693 Sensitive: D – Preclinical GSK690693 Sensitive : D	GSK690693 Sensitive: D – Preclinical GSK690693 Sensitive : D